Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects to begin enrolling patients in a first-in-human Phase 1 trial in the fourth quarter of 2026. The study will assess the candidate alone and in combination with other treatments. The planned open-label, multicenter trial will examine safety, drug exposure, pharma
0